Adenoviral vector immunity: its implications and circumvention strategies

Curr Gene Ther. 2011 Aug;11(4):307-20. doi: 10.2174/156652311796150372.

Abstract

Adenoviral (Ad) vectors have emerged as a promising gene delivery platform for a variety of therapeutic and vaccine purposes during last two decades. However, the presence of preexisting Ad immunity and the rapid development of Ad vector immunity still pose significant challenges to the clinical use of these vectors. Innate inflammatory response following Ad vector administration may lead to systemic toxicity, drastically limit vector transduction efficiency and significantly abbreviate the duration of transgene expression. Currently, a number of approaches are being extensively pursued to overcome these drawbacks by strategies that target either the host or the Ad vector. In addition, significant progress has been made in the development of novel Ad vectors based on less prevalent human Ad serotypes and nonhuman Ad. This review provides an update on our current understanding of immune responses to Ad vectors and delineates various approaches for eluding Ad vector immunity. Approaches targeting the host and those targeting the vector are discussed in light of their promises and limitations.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Adenoviridae / genetics*
  • Adenoviridae / immunology*
  • Animals
  • Capsid / metabolism
  • Gene Expression
  • Gene Transfer Techniques
  • Genetic Therapy
  • Genetic Vectors / immunology*
  • Genetic Vectors / toxicity
  • Helper Viruses / metabolism
  • Humans
  • Immunity, Innate
  • Immunosuppression
  • Transduction, Genetic
  • Transgenes
  • Vaccines / genetics
  • Vaccines / immunology

Substances

  • Vaccines